Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

Completed

• Conditions: Type2 Diabetes

• Registration Number: NCT03362112
• Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Brief Summary

Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).

Detailed Description

The investigators recorded clinical factors, serum levels of glucose, HbA1c, lipids and LP-PLA2 in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016. The relationship between levels of LP-PLA2 and diabetic complications are analysed.

Study Timeline

• Study Start: 2015-01-30
• Primary Completion: 2016-08-31
• Study Completion: 2017-06-01
• Status Verified: 2017-11
• Study First Submitted: 2017-11-29
• Study First Submitted QC: 2017-11-29
• Study First Posted: 2017-12-05
• Results First Submitted: 2019-06-09
• Results First Submitted QC: 2022-04-12
• Last Update Submitted: 2022-04-12
• Results First Posted: 2022-04-14
• Last Update Posted: 2022-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1713

Inclusion Criteria

• Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.

Exclusion Criteria

1. Patients use systemic steroidal anti-inflammatory drugs.
2. Patients are pregnant.
3. Patients with an acute infection.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Lipoprotein-associated Phospholipase A2	Day one	the plasma lipoprotein-associated phospholipase A2 level of patients

Secondary Outcome Measures

Name	Time	Method
Diabetic Complication	Day one	the prevalence of atherosclerosis, diabetic Nephropathy, diabetic retinopathy and diabetic neuropathy
HbA1c	Day one	the glycosylated hemoglobin level of patients
LDL-c	Day one	low density lipoprotein cholesterol
C Peptide	Day one	fast and 120min postprandial C peptide